Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

While the prevalence of financial precarity varied by scenario, the proportion of beneficiaries who could not pay their hospital bill across ... stool DNA test (Exact Sciences Cologuard) vs.

Perhaps, that was the exact time she thought "If Joe's diminishing brain functions ... Fortunately, with the advancement of technology and Cologuard Test Kits, future Presidents can continue to ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... 1.2 million patients including a record number with Cologuard and Etty DX. Growing total revenue 13% ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences' Q3 earnings report has led to a ... Exact's main sources of revenues are its Cologuard test, a "patient-friendly, non-invasive stool-based DNA screening test that utilizes a ...